Press releaseGlobe Newswire
Vivani Medical
VANI · NASDAQ
$1.12+$0.00 (+0.00%)TodayMarket closed ·
Prev close $1.12
Latest news
- Press releaseBusiness Wire
ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical
- News
Vivani Medical Receives Approval From Australian Human Research Ethics Committee Bellberry To Initiate SLIM-1, A Phase 1 Clinical Trial Of Semaglutide Implant NPM-139
- Press releaseGlobe Newswire
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseGlobe Newswire
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results
- News
Vivani Sets October 8 Record Date For Spin-Off Of Cortigent, To Trade Under Nasdaq Ticker 'CRGT'
- Press releaseGlobe Newswire
Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
- News
Vivani Medical Plans To Initiate Phase 1 Clinical Study In NPM-139 Semaglutide Implant Program In First Half Of 2026, Pending Regulatory Clearance
- Press releaseGlobe Newswire
Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
- Press releaseGlobe Newswire
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
- NewsVandana Singh
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- NewsVandana Singh
EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing
- Press releaseBusiness Wire
Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025
- Press releaseBusiness Wire
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
- Press releaseBusiness Wire
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
- Press releaseBusiness Wire
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
- News
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
- Press releaseBusiness Wire
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
- Press releaseBusiness Wire
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results
- News
Reported Earlier, 'Novo Nordisk's Ozempic and Wegovy, long in shortage, are now listed as available by FDA; It remains unclear how the update could affect patients as well as compounders' - STAT News
- Press releaseBusiness Wire
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
- Press releaseBusiness Wire
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
- Press releaseBusiness Wire
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
- Press releaseBusiness Wire
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
- NewsVandana Singh
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
- Press releaseBusiness Wire
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Press releaseBusiness Wire
Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
- NewsAvi Kapoor
Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying
- Press releaseBusiness Wire
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
- NewsVandana Singh
EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.